Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

• The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma.

• The secondary purposes of the study are to determine the safety and to evaluate whether there is additional benefit from Zevalin therapy following the chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Biogen; Massachusetts General Hospital
• Treatments: Antibodies, Monoclonal; Fludarabine; Fludarabine phosphate; Mitoxantrone; Rituximab; Vidarabine

Criteria

Inclusion Criteria:

• Histologically confirmed mantle cell lymphoma in 1st or 2nd relapse, or with persistent disease following induction therapy.

• Measurable disease (lymph node > 1.5 cm)

• No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, and fully recovered from all toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy

• An IRB-approved signed informed consent

• Age >/= 18 years

• Expected survival >/= 3 months

• ECOG performance status 0, 1, or 2

• Acceptable hematologic status within two weeks prior to registration, including: * Absolute neutrophil count ([segmented neutrophils + bands] x total WBC) ≥ 1,500/mm3; * Platelet counts ≥ 100,000/mm3

• Female patients who are not pregnant or lactating

• Men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician, however abstinence is not an acceptable method)

• Patients previously on Phase II drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed

Inclusion Criteria for Proceeding with Zevalin:

• Hematologic recovery from FMR (ANC >1500, platelets > 100,000)

• Stable or responding disease on restaging following two cycles of FMR

• < 25% of bone marrow cellularity involved with lymphoma on restaging bone marrow biopsy

• Bone marrow cellularity at least 20% (including lymphoma and normal cells)

• Total bilirubin < 2.0 mg/dL (if total bilirubin is >75% indirect, then may use direct bilirubin < 0.8 mg/dL)

• Serum creatinine < 2.0 mg/dL

• No G-CSF or GM-CSF therapy within two weeks prior to Zevalin treatment, or neulasta within four weeks prior to Zevalin treatment

• No evidence of altered biodistribution of 111-In-Zevalin as indicated by:

1. Absent cardiac blood pool on day 1, with high liver / spleen uptake

2. Lung uptake greater than blood pool on day 1 or greater than liver on day 2-3

3. Kidney (in posterior view) or bowel uptake greater than liver on day 2-3

Exclusion Criteria:

• Patients with impaired bone marrow reserve, as indicated by one or more of the following: * Prior myeloablative therapies with allogeneic or autologous bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue; * Platelet count < 100,000 cells/mm3; * Prior external beam radiation to >25% of active bone marrow; * History of failed stem cell collection

• Prior radioimmunotherapy

• Known cardiac ejection fraction < 40%. In patients with prior adriamycin exposure >= 300 mg/m2, echocardiogram must be obtained within three months prior to registration

• Known CNS lymphoma (lumbar puncture only required if symptomatic)

• Chronic lymphocytic leukemia (CLL)

• HIV or AIDS-related lymphoma

• Pleural effusion or ascites

• Abnormal liver function: total bilirubin > 2.0 mg/dL (if total bilirubin is >75% indirect, then may use direct bilirubin > 0.8 mg/dL)

• Abnormal renal function: serum creatinine > 2.0 mg/dL

• G-CSF or GM-CSF therapy within two weeks prior to treatment, or neulasta within four weeks

• Positive direct antiglobulin test

• Major surgery, other than diagnostic surgery, within four weeks

• Serious nonmalignant disease or infection which in the opinion of the investigator would compromise protocol objectives